Who is sponsoring NCT03470961?

NCT03470961 is sponsored by Tianjin First Central Hospital.

What drugs are being tested in NCT03470961?

Interventions in NCT03470961: Anti-Tlymphocyte Globulins, Anti-Thymocyte Globulins.

What condition does NCT03470961 study?

NCT03470961 studies CKD (Chronic Kidney Disease) Stage 5T, Diabetes Mellitus, Simultaneous Pancreas Kidney Transplantation.

Is NCT03470961 still recruiting?

NCT03470961 is currently status unknown. Last updated 20 March 2018.

Last reviewed 2018-03-20 · How we verify

NCT03470961: PAISPK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Observational Study to Evaluate the Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients

Status unknown Phase 4 Last updated 20 March 2018

What this trial tests

Phase 4 trial testing Anti-Tlymphocyte Globulins in CKD (Chronic Kidney Disease) Stage 5T in 45 participants. Status unknown.

Timeline

1 March 2018

Primary endpoint
1 March 2021

1 March 2021

Quick facts

Lead sponsor	Tianjin First Central Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	45
Start date	1 March 2018
Primary completion	1 March 2021
Estimated completion	1 March 2021
Sites	1 location across China

Drugs / interventions tested

Anti-Tlymphocyte Globulins — full drug profile →
Anti-Thymocyte Globulins — full drug profile →

Conditions studied

CKD (Chronic Kidney Disease) Stage 5T — all drugs for CKD (Chronic Kidney Disease) Stage 5T →
Diabetes Mellitus — all drugs for Diabetes Mellitus →
Simultaneous Pancreas Kidney Transplantation — all drugs for Simultaneous Pancreas Kidney Transplantation →

Sponsor

Tianjin First Central Hospital

Who can join

Adults 18 to 60, any sex, with CKD (Chronic Kidney Disease) Stage 5T or Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A single-centre, prospective, observational study to evaluate the safety and efficacy of Polyclonal Antibodies in simultaneous Pancreas Kidney Transplant recipients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Tianjin First Central Hospital trials

Trials by the same sponsor.

NCT06598228 — Acute Kidney Injury and Recovery Mode in Pediatric Liver Transplantation · completed
NCT05752058 — Risk Factors for Early Acute Lung Injury After Liver Transplantation in Children · unknown
NCT05926076 — COVID-19 Infection · unknown
NCT05807802 — FSTL1 and PPCs on Pediatric Within LDLT:a Prospective Cohort Analysis · unknown
NCT05783518 — Effect of Desflurane on Pediatric Acute Respiratory Distress Syndrome After Living Donor Liver Transplant Recipients · Phase 4 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03470961 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin First Central Hospital
Last refreshed: 20 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03470961.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing